Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with L
Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
---|---|---|---|---|---|---|---|
Q3 2022 | LACTOSE MONOHYDRATE | ORAL | TABLET, COATED PARTICLES | 150.00 mg | Deletion | ||
Q2 2022 | LACTOSE MONOHYDRATE | ORAL | GRANULE, FOR SOLUTION | 1691.80 mg | MDE Replacement | ||
Q3 2022 | LACTOSE MONOHYDRATE | ORAL | GRANULE, FOR SOLUTION | 846mg | MDE Replacement | ||
Q2 2022 | LACTOSE MONOHYDRATE | ORAL | TABLET, FOR SUSPENSION | 543.60 mg | MDE Replacement | ||
Q3 2022 | LACTOSE MONOHYDRATE | ORAL | TABLET, FOR SUSPENSION | 2794mg | MDE Replacement | ||
Q2 2022 | LECITHIN | ORAL | SUSPENSION | 110.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | LECITHIN | ORAL | SUSPENSION | 150mg | MDE Replacement | ||
Q2 2022 | LIME OIL, COLD PRESSED | ORAL | LOZENGE | 0.42 mg | MDE Replacement | ||
Q3 2022 | LIME OIL, COLD PRESSED | ORAL | LOZENGE | 10mg | MDE Replacement | ||
Q2 2022 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | ORAL | TABLET, DELAYED RELEASE | 30.99 mg | MDE Replacement | ||
Q3 2022 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | ORAL | TABLET, DELAYED RELEASE | 103mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022